SNY Articles, Sanofi - From 04/29/24

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Pha...

U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday. Shares of Sanofi SA (NASDAQ:SNY) rose sharply during Thursday'...

Thursday, Sanofi SA (NASDAQ:SNY) reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on const...

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...

As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...

Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in...

Novartis AG (NYSE:NVS) released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ...

Sanofi SA (NASDAQ:SNY) reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis. What Happened: The company’s CD40...

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...